Emerging biomarkers in cognition

Clinics in Geriatric Medicine

Volumn 29, Issue 4, 2013, Pages 809-828

  Wicklund, Meredith ^a   Petersen, Ronald C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Alzheimer disease; Biomarkers; Dementia

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; FLORBETAPIR F 18; GLIAL FIBRILLARY ACIDIC PROTEIN; PITTSBURGH COMPOUND B; PROTEIN S100B; TAR DNA BINDING PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; VISININ LIKE PROTEIN 1;

ALZHEIMER DISEASE; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN METABOLISM; CEREBROSPINAL FLUID ANALYSIS; COGNITION; CORTICAL THICKNESS (BRAIN); DIFFUSE LEWY BODY DISEASE; DIFFUSION TENSOR IMAGING; FRONTOTEMPORAL DEMENTIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPUS; HUMAN; INFLAMMATION; LIPIDOMICS; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; BIOMARKERS; DEMENTIA;

AGED; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; BRAIN; HUMANS; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 84884789456     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2013.07.006     Document Type: Review

References (134)

1. Jack C.R., Knopman D.S., Weigand S.D., et al. An operational approach to NIA-AA criteria for preclinical Alzheimer's disease. Ann Neurol 2012, 71(6):765-775.
2. Knopman D.S., Jack C.R., Wiste H.J., et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012, 78:1576-1582.
3. Sperling R.A., Aisen P.S., Beckett L.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
4. Petersen R.C., Smith G.E., Waring S.C., et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56:303-308.
5. Petersen R.C. Mild cognitive impairment as a diagnostic entity. JIntern Med 2004, 256:183-194.
6. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003, 2:15-21.
7. Gauthier S., Reisberg B., Zaudig M., et al. Mild cognitive impairment. Lancet 2006, 367:1262-1270.
8. Winblad B., Palmer K., Kivipelto M., et al. Mild cognitive impairment - beyond controversies, towards a consensus. JIntern Med 2004, 256:240-246.
9. Albert M.S., DeKosky S.T., Dickson D., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association Workgroup. Alzheimers Dement 2011, 7:270-279.
10. Hyman B.T., Phelps C.H., Beach T.G., et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012, 8:1-13.
11. Clark C.M., Schneider J.A., Bedell B.J., et al. Use of florbetapir-PET for imaging B-amyloid pathology. JAMA 2011, 305:275-283.
12. Koyama A., Okereke O.I., Yang T., et al. Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol 2012, 69(7):824-831.
13. Klunk W.E., Engler H., Nordberg A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004, 55:306-319.
14. Wong D.F., Rosenberg P.B., Zhou Y., et al. Invivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). JNucl Med 2010, 51:913-920.
15. Kemppainen N.M., Aalto S., Wilson I.A., et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006, 67:1575-1580.
16. Chetelat G., Villemagne V.L., Pike K.E., et al. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain 2011, 134:798-807.
17. Bacskai B.J., Frosch M.P., Freeman S.H., et al. Molecular imaging with Pittsburgh compound B confirmed at autopsy: a case report. Arch Neurol 2007, 64:431-434.
18. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., et al. Post-mortem correlates of invivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645.
19. Rosen R.F., Ciliax B.J., Wingo T.S., et al. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathol 2010, 119(2):221-233.
20. Wolk D.A., Price J.C., Saxton J.A., et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009, 65:557-568.
21. Villemagne V.L., Pike K.E., Chetelat G., et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 2011, 69:181-192.
22. Doraiswamy P.M., Sperling R.A., Coleman R.E., et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012, 79:1636-1644.
23. Landau S.M., Mintun M.A., Joshi A.D., et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012, 72(4):578-586.
24. Jack C.R., Wiste H.J., Vemuri P., et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 2010, 133:3336-3348.
25. Strozyk D., Blennow K., White L.R., et al. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003, 60:652-656.
26. Clark C.M., Xie S., Chittams J., et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol 2003, 60:1696-1702.
27. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003, 2:605-613.
28. Hansson O., Zetterberg H., Buchhave P., et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006, 5:228-234.
29. Mattsson N., Zetterberg H., Hansson O., et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302:385-393.
30. Riemenschneider M., Lautenschlager N., Wagenpfeil S., et al. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 2002, 59:1729-1734.
31. Fagan A.M., Mintun M.A., Mach R.H., et al. Inverse relation between invivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006, 59:512-519.
32. Jagust W.J., Landau S.M., Shaw L.M., et al. Relationships between biomarkers in aging and dementia. Neurology 2009, 73:1193-1199.
33. Grimmer T., Riemenschneider M., Forstl H., et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 2009, 65:927-934.
34. Tolboom N., van der Flier W.M., Yaqub M., et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. JNucl Med 2009, 50:1464-1470.
35. Terry R.D., Masliah E., Salmon D.P., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30:572-580.
36. Apostolova L.G., Dutton R.A., Dinov I.D., et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch Neurol 2006, 63:693-699.
37. Jack C.R., Weigand S.D., Shiung M.M., et al. Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology 2008, 70:1740-1752.
38. Bobinski M., de Leon M.J., Wegiel J., et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 2000, 95:721-725.
39. Jack C.R., Petersen R.C., Xu Y.C., et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999, 52:1397-1403.
40. Bakkour A., Morris J.C., Dickerson B.C. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology 2009, 72:1048-1055.
41. van de Pol L.A., van der Flier W.M., Korf E.S., et al. Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology 2007, 69:1491-1497.
42. Fischl B., Salat D.H., Busa E., et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002, 33:341-355.
43. Jack C., Barkhof F., Bernstein M., et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criteria for Alzheimer's disease. Alzheimers Dement 2011, 7(4):474-485.
44. Attwell D., Laughlin S.B. An energy budget for signaling in the grey matter of the brain. JCereb Blood Flow Metab 2001, 21:1133-1145.
45. Schwartz W.J., Smith C.B., Davidsen L., et al. Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science 1979, 205:723-725.
46. Jagust W., Reed B., Mungas D., et al. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?. Neurology 2007, 69:871-877.
47. Hoffman J.M., Welsh-Bohmer K.A., Hanson M., et al. FDG PET imaging in patients with pathologically verified dementia. JNucl Med 2000, 41:1920-1928.
48. Ibanez V., Pietrini P., Alexander G.E., et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1998, 50:1585-1593.
49. Reiman E.M., Caselli R.J., Lang S., et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the E4 allele for apolipoprotein E. NEngl J Med 1996, 334:752-758.
50. Reiman E.M., Caselli R.J., Chen K., et al. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 2001, 98:3334-3339.
51. Chetelat G., Desgranges B., de la Sayette V., et al. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology 2003, 60:1374-1377.
52. Landau S.M., Harvey D., Madison C.M., et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010, 75:230-238.
53. Jagust W., Budinger T.F., Reed B.R. The diagnosis of dementia with single photon emission computed tomography. Arch Neurol 1987, 44:258-262.
54. Kanetaka H., Matsuda H., Asada T., et al. Effects of partial volume correction on discrimination between very early Alzheimer's dementia and controls using brain perfusion SPECT. Eur J Nucl Med Mol Imaging 2004, 31:975-980.
55. Bradley K.M., O'Sullivan V.T., Soper N.D., et al. Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain 2002, 125:1772-1781.
56. Borroni B., Anchisi D., Paghera B., et al. Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD. Neurobiol Aging 2006, 27:24-31.
57. Hirao K., Ohnishi T., Hirata Y., et al. The prediction of rapid conversion to Alzheimer's disease in mild cognitive impairment using regional cerebral blood flow SPECT. Neuroimage 2005, 28:1014-1021.
58. Herholz K., Schopphoff H., Schmidt M., et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. JNucl Med 2002, 43:21-26.
59. Messa C., Perani D., Lucignani G., et al. High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer's disease: comparison with fluorine-18-FDG PET. JNucl Med 1994, 35:210-216.
60. Arai H., Terajima M., Miura M., et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 1995, 38:649-652.
61. Blennow K., Wallin A., Agren H., et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol Chem Neuropathol 1995, 26:231-245.
62. Tapiola T., Overmyer M., Lehtovirta M., et al. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. Neuroreport 1997, 8:3961-3963.
63. Jagust W., Thisted R., Devous M.D., et al. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study. Neurology 2001, 56:950-956.
64. Andreasen N., Minthon L., Clarberg A., et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 1999, 53:1488-1494.
65. Morikawa Y.I., Arai H., Matsushita S., et al. Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics. Alcohol Clin Exp Res 1999, 23:575-577.
66. Sjögren M., Minthon L., Davidsson P., et al. CSF levels of tau, β-amyloid 1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. JNeural Transm 2000, 107:563-579.
67. Hesse C., Rosengren L., Andreasen N., et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001, 297:187-190.
68. Ost M., Nylen K., Csajbok L., et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 2006, 67:1600-1604.
69. Otto M., Wiltfang J., Cepek L., et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002, 58:192-197.
70. Grundke-Iqbal I., Iqbal K., Tung Y.C., et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986, 83:4913-4917.
71. Riemenschneider M., Wagenpfeil S., Vanderstichele H., et al. Phospho-tau//total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatry 2003, 8:343-347.
72. Sjogren M., Davidsson P., Tullberg M., et al. Both total and phosphorylated tau are increased in Alzheimer's disease. JNeurol Neurosurg Psychiatry 2001, 70:624-630.
73. Parnetti L., Lanari A., Amici S., et al. CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Neurol Sci 2001, 22:77-78.
74. Herukka S.K., Hallikainen M., Soininen H., et al. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005, 64:1294-1297.
75. Van Rossum I.A., Vos S., Handels R., et al. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. JAlzheimers Dis 2010, 20:881-891.
76. Jeong Y., Cho S.S., Park J.M., et al. 18F-FDG PET Findings in frontotemporal dementia: an SPM analysis of 29 patients. JNucl Med 2005, 46:233-239.
77. Foster N.L., Heidebrink J.L., Clark C.M., et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007, 130:2616-2635.
78. McNeill R., Sare G.M., Manoharan M., et al. Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer's disease. JNeurol Neurosurg Psychiatry 2007, 78:350-355.
79. Taylor K.I., Probst A., Miserez A.R., et al. Clinical course of neuropathologically confirmed frontal-variant Alzheimer's disease. Nat Clin Pract Neurol 2008, 4:226-232.
80. Minoshima S., Foster N.L., Sima A.A., et al. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001, 50:358-365.
81. O'Brien J., Colloby S., Fenwick J., et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004, 61:919-925.
82. McKeith I., O'Brien J., Walker Z., et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007, 6:305-313.
83. Walker Z., Costa D.C., Walker R.W., et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. JNeurol Neurosurg Psychiatry 2002, 73:134-140.
84. Hansen L.A., Samuel W. Criteria for Alzheimer's disease and the nosology of dementia with Lewy bodies. Neurology 1997, 48:126-132.
85. Jack C., Knopman D., Jagust W., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
86. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
87. Jack C., Low V., Weigand S., et al. Serial PiB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365.
88. Jack C.R., Wiste H.J., Lesnick T.G., et al. Brain β-amyloid load approaches a plateau. Neurology 2013, 80(10):890-896.
89. Buchhave P., Minthon L., Zetterberg H., et al. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012, 69:98-106.
90. Engler H., Forsberg A., Almkvist O., et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006, 129:2856-2866.
91. Vemuri P., Wiste H.J., Weigand S.D., et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009, 73:294-301.
92. Fox N.C., Freeborough P.A. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. JMagn Reson Imaging 1997, 7:1069-1075.
93. Wahlund L.O., Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 2003, 339:99-102.
94. Whitwell J.L., Przybelski S.A., Weigand S.D., et al. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain 2007, 130:1777-1786.
95. Galasko D., Hansen L.A., Katzman R., et al. Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 1994, 51:888-895.
96. Jellinger K.A. Diagnostic accuracy of Alzheimer's disease: a clinicopathological study. Acta Neuropathol 1996, 91:219-220.
97. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999, 45:358-368.
98. Lopez O.L., Jagust W.J., DeKosky S.T., et al. Prevalence and classification of mild cognitive impairment in the cardiovascular health study cognition study. Arch Neurol 2003, 60:1385-1389.
99. Ganguli M., Dodge H.H., Shen C., et al. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology 2004, 63:115-121.
100. Petersen R.C., Roberts R.O., Knopman D.S., et al. Prevalence of mild cognitive impairment is higher in men: the Mayo Clinic study of aging. Neurology 2010, 75:889-897.
101. Ly J.V., Donnan G.A., Villemagne V.L., et al. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology 2010, 74:487-493.
102. Johnson K.A., Gregas M., Becker J.A., et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007, 62:229-234.
103. Kanemaru K., Kameda N., Yamanouchi H. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 2000, 54:1875-1876.
104. Otto M., Esselmann H., Schulz-Shaeffer W., et al. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 2000, 54:1099-1102.
105. Sjogren M., Davidsson P., Wallin A., et al. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement Geriatr Cogn Disord 2002, 13:112-118.
106. Holmberg B., Johnels B., Blennow K., et al. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov Disord 2003, 18:186-190.
107. Laterza O.F., Modur V.R., Crimmins D.L., et al. Identification of novel brain biomarkers. Clin Chem 2006, 52:1713-1721.
108. Tarawneh R., Lee J.M., Ladenson J.H., et al. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 2012, 78:709-719.
109. de Leon M.J., DeSanti S., Zinkowski R., et al. Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging 2006, 27:394-401.
110. de Leon M.J., Mosconi L., Li J., et al. Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. JNeurol 2007, 254:1666-1675.
111. Drago V., Babiloni C., Bartres-Faz D., et al. Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage. JAlzheimers Dis 2011, 26(Suppl 3):159-199.
112. Craig-Schapiro R., Perrin R.J., Roe C.M., et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 2010, 68:903-912.
113. Panza F., Solfrizzi V., Seripa D., et al. Peripheral antioxidant markers in mild cognitive impairment and its progression to dementia. JAlzheimers Dis 2010, 21:1179-1183.
114. Wood P.L. Lipidomics of Alzheimer's disease: current status. Alzheimers Res Ther 2012, 4:5.
115. Mielke M.M., Bandaru V.V., Haughey N.J., et al. Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II. Neurology 2012, 79:633-641.
116. Mielke M.M., Haughey N.J., Ratnam Bandaru V.V., et al. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement 2010, 6:378-385.
117. Kantarci K., Jack C.R., Xu Y.C., et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology 2000, 55:210-217.
118. Kantarci K. 1H magnetic resonance spectroscopy in dementia. Br J Radiol 2007, 80(Spec No 2):S146-S152.
119. Kantarci K., Petersen R.C., Przybelski S.A., et al. Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. Arch Neurol 2008, 65:1621-1628.
120. Kantarci K., Petersen R.C., Boeve B.F., et al. 1H MR spectroscopy in common dementias. Neurology 2004, 63:1393-1398.
121. MacKay S., Meyerhoff D.J., Constans J.M., et al. Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging. Arch Neurol 1996, 53:167-174.
122. Kattapong V.J., Brooks W.M., Wesley M.H., et al. Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia. Arch Neurol 1996, 53:678-680.
123. Fox M.D., Snyder A.Z., Vincent J.L., et al. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci USA 2005, 102:9673-9678.
124. Jack C.R. Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology 2012, 263:344-361.
125. Alsop D.C., Detre J.A., Grossman M. Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann Neurol 2000, 47:93-100.
126. Du A.T., Jahng G.H., Hayasaka S., et al. Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI. Neurology 2006, 67:1215-1220.
127. Chen Y., Wolk D.A., Reddin J.S., et al. Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology 2011, 77:1977-1985.
128. Hu W.T., Wang Z., Lee V.M., et al. Distinct cerebral perfusion patterns in FTLD and AD. Neurology 2010, 75:881-888.
129. Mollenhauer B., Cullen V., Kahn I., et al. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 2008, 213:315-325.
130. Kasuga K., Tokutake T., Ishikawa A., et al. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. JNeurol Neurosurg Psychiatry 2010, 81:608-610.
131. Noguchi-Shinohara M., Tokuda T., Yoshita M., et al. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res 2009, 1251:1-6.
132. Reesink F.E., Lemstra A.W., van Dijk K.D., et al. CSF alpha-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. JAlzheimers Dis 2010, 22:87-95.
133. de Jong D., Jansen R.W., Pijnenburg Y.A., et al. CSF neurofilament proteins in the differential diagnosis of dementia. JNeurol Neurosurg Psychiatry 2007, 78:936-938.
134. Steinacker P., Hendrich C., Sperfeld A.D., et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol 2008, 65:1481-1487.